Lupin plans to list subsidiaries it has been setting up in the recent past
Promoters don’t intend selling their stake in Lupin, no intention to acquire Cipla
An alliance with Mark Cuban’s Cost Plus Drug could add a few more drugs
Subsidiaries like Lupin Digital, Atharv Ability along with patient support programs aimed at creating a healthcare continuum
A transformative acquisition is not planned for the biosimilars business
Diagnostics was first “consumer-centric” business, helps understand prescription behavior
R&D activity to be primarily focused on oncology
One-third of Lupin’s API Business to be spun out by Q4FY23, to be transferred to subsidiary Lupin Manufacturing
Contract Development and Manufacturing plans are at a nascent stage

A Decade At The Top: Lupin MD On Listing Adjacencies, Creating Healthcare Continuum

Promoters Don’t Intend Selling Stake